CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Intellect Neurosciences, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Intellect Neurosciences, Inc.
550 Sylvan Avenue
Suite 101
Phone: (201) 608-5102p:201 608-5102 Englewood Cliffs, NJ  07632-3115  United States Fax: (212) 448-9600f:212 448-9600

This company is no longer actively traded on any major stock exchange.

Business Summary
Intellect Neurosciences, Inc., is a biopharmaceutical company. The Company, together with its subsidiary, Intellect Neurosciences, USA, Inc. (Intellect USA), is engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare, neurodegenerative, orphan diseases with no approved therapies. The Company is focused on developing each compound and licenses the compounds to pharmaceutical companies for development and commercialization. Its product pipeline consists of SHP622, Anti-Tauc3 Monoclonal Antibody and Conjumab-A: Antibody Drug Conjugate. SHP622 is indicated for the treatment of Friedreich's Ataxia and Other Neurodegenerative Disorders. Anti-Tauc3 Monoclonal Antibody is indicated for the treatment of progressive supranuclear palsy, traumatic brain injury and other Tauopathies. Conjumab-A: Antibody Drug Conjugate is indicated for the treatment of age-related macular degeneration.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20166/30/2015YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Director Elliot M.Maza 61 7/30/2014 5/1/2006
Independent Director IsaacOnn 66 5/4/2010 5/4/2010

Business Names
Business Name
GlobePan Resources, Inc.
ILNS
Intellect Neurosciences Inc.
Intellect Neurosciences, Inc.

General Information
Outstanding Shares: 6,520,389 (As of 5/9/2016)
Shareholders: 88
Stock Exchange: OTC
Federal Tax Id: 202777006
Fax Number: (212) 448-9600


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023